This segment focuses on the research, development, and commercialization of molecular imaging pharmaceuticals for cardiology applications. The primary technology utilized is Positron Emission Tomography (PET) imaging. Research and development activities include the ongoing clinical trials of CardioPET, a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with coronary artery disease (CAD). The company also has BFPET, an imaging agent that has completed a Phase I clinical trial for stress-testing in patients with CAD. The patient impact is improved diagnosis and assessment of heart disease, leading to better treatment decisions and outcomes. FluoroPharma's market positioning is as a developer of innovative diagnostic tools in a market with significant unmet needs. Future opportunities include expanding the applications of their imaging agents and potentially developing new agents for other cardiovascular conditions. Clinical trials and regulatory approvals are critical aspects of this segment, and the company has partnerships with organizations like Massachusetts General Hospital and Pharmaceutical Product Development, LLC.